The Letter of Intent is an important step for patients living with a post-transplant cytomegalovirus (CMV) infection to have public access to treatment.
"One of the key priorities of the Canadian Immunocompromised Advocacy Network is striving to ensure immunocompromised patients across
Timing of each listing will be dependent on the respective province or territory. LIVTENCITY is already covered by a majority of private insurance plans.
"Takeda remains dedicated to increasing accessibility to vital treatment options for all Canadians suffering with a post-transplant cytomegalovirus (CMV) infection," said
LIVTENCITY is a selective orally bioavailable benzimidazole riboside antiviral drug with a novel mechanism of action against human CMV (HCMV).1 LIVTENCITY attaches to the UL97 encoded kinase at the adenosine triphosphate (ATP) binding site, as a consequence abolishing phosphotransferase needed in processes such as DNA replication, encapsidation, and nuclear egress of viral capsids.1
For contraindications, warnings, precautions, adverse reactions, drug-drug interactions, dosing, and conditions of clinical use, consult the LIVTENCITY product monograph at https://assets-dam.takeda.com/image/upload/legacy-dotcom/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/livtencity/LIVTENCITY-PM-Eng.pdf
CMV, a beta herpesvirus, commonly infects people around the world; serologic evidence of infection can be found in 40%-100% of various adult populations.2 Typically CMV remains dormant and asymptomatic in the body, however this virus may reactivate during periods of immunosuppression. Patients with compromised immune systems such as those
Out of the estimated 200,000 transplants in adults per year globally, CMV is one of the most common viral infections experienced by transplant recipients, with an estimated incidence rate between 16%-56% in SOT recipients and 30%-70% in HSCT recipients.3,5,6,7 If untreated, CMV infection in transplant patients can lead to serious outcomes such as the loss of the transplanted organ and, in extreme cases, can be fatal.2,8
LIVTENCITY® and the LIVTENCITY Logo® are registered trademarks of
TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited, used under license.
1 LIVTENCITY® Product Monograph. |
2 de la Hoz R. Diagnosis and treatment approaches to CMV infections in adult patients. J Clin Virol. 2002;25:S1-S12. |
3 Azevedo L, Pierrotti L, Abdala E, et al. Cytomegalovirus infection in transplant recipients. Clinics. 2015;70(7):515-523. |
4 Razonable RR, Eid AJ. A Viral infections in transplant recipients. Minerva Med. 2009;100(6):23. |
5 Shannon-Lowe & Emery. The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae 2010, 1:4. |
6 Styczynski J. |
7 |
8 Kenyon M, Babic A, eds. The European Blood and Marrow Transplantation Textbook for Nurses. |
SOURCE
© Canada Newswire, source